Reported treatment patterns (n = 301). (A) Commonly administered treatments (median percentage of patients receiving treatment in indicated setting). (B). Top 3 ranked non-cisplatin first-line therapies (percentage of respondents). Chemo, chemotherapy. aCancer immunotherapy/immunotherapy (n = 9) and Bacillus Calmette-Guérin, carboplatin, clinical trial, radiotherapy, sparing (n = 1 each). bNivolumab and other chemo (less than 1% each) not plotted. cAvelumab and clinical trial (n = 1 each). dRanked first by 2%. eRanked first by 1%.